Posted by Michael Wonder on 27 Jan 2023
Valeo Pharma announces filing of a new drug submission with Health Canada for sabizabulin for the treatment of hospitalised COVID-19 patients
26 January 2023 - In the final analysis of the Phase 3 clinical study conducted by Veru, sabizabulin showed a 51.6% reduction in deaths compared to placebo in hospitalised adult patients with moderate to severe COVID-19 who are at high risk for ARDS.
Valeo Pharma announced today that Health Canada has accepted for review Veru's new drug submission for sabizabulin for COVID-19.
